


# 4D-Nucleofector™ Protocol for Suspension HEK293 Cells For 4D-Nucleofector™ LV Unit

Human embryonic kidney cells; adapted to suspension growth

**Important:** Before performing an experiment in the 4D-Nucleofector™ LV Unit it is recommended to establish optimal cell and substrate concentrations in small scale using the 4D-Nucleofector™ X Unit. Conditions are transferable from the 4D-Nucleofector™ X Unit to the LV Unit.

## Example for Nucleofection of Suspension HEK293 Cells

Transfection efficiency and viability of suspension HEK293 cells 24 hours post Nucleofection. Freestyle™ 293-F (Thermo Fisher) ( $5 \times 10^7$  cells/mL) were transfected with pmaxGFP™ Vector (40 µg/mL) using program FS-100 in 100 µL Nucleocuvette™ Vessels or with 20 mL in LV Nucleocuvette™ Cartridges. 24 hours post Nucleofection, transfection efficiency was analyzed on a FACSCalibur™ (Becton Dickinson). Cell viability was determined via propidium iodide (PI) staining. Data represent the mean of various independent experiments.



## Product Description

### Recommended Kit(s) – SF Cell Line 4D-Nucleofector™ LV Kit

Cat No.	V4LC-2002	V4LC-2020
Transfection volume	1 mL	1 – 20 mL
Size [reaction]	2	1
Nucleofector™ Solution	2.25 mL	22.5 mL
Supplement	0.5 mL	5 mL
1 mL Nucleocuvette™ Cartridge	2	-
LV Nucleocuvette™ Cartridge	-	1
4D-Nucleofector™ LV Reservoir	-	2

### Storage and Stability

Store Nucleofector™ Solution and Supplement at 4°C. The expiration date is printed on the solution box. Once the Nucleofector™ Supplement is added to the Nucleofector™ Solution, it is stable for three months at 4°C.

### Note

4D-Nucleofector™ Solutions can only be used with conductive polymer Nucleocuvette™ Vessels, i.e. in the 4D-Nucleofector™ System, the 96-well Shuttle™ System or the HT Nucleofector™ System. They are not compatible with the Nucleofector™ II/2b Device.

## Required Material

### Note

Please make sure that the entire supplement is added to the Nucleofector™ Solution prior to use. For preparing aliquots, mix Nucleofector™ Solution and Supplement in a ratio of 4.5 : 1 (see Table 1).

- 4D-Nucleofector™ System (4D-Nucleofector™ Core and LV Unit)
- Supplemented 4D-Nucleofector™ Solution at room temperature
- Supplied 1 mL Nucleocuvette™ Cartridge or LV Nucleocuvette™ Cartridge
- For loading cell suspension into 1 mL Nucleocuvette™ Cartridges: Compatible tips, e.g. OneTouch pipet tips, 1250 µL (Sorenson™ BioScience Inc., Cat. No. 10370; via VWR, Cat. No. 89082-348)
- For working with LV Nucleocuvette™ Cartridges:
  - Supplied 4D-Nucleofector™ LV Reservoirs (alternatively you may use bags). Additional reservoirs can be ordered separately (Lonza, Cat. No. V4LR-1001)
  - Magnetic stirrer, e.g. MR Hei-Tec (Heidolph, Cat. No. 036110550)
  - BD Falcon™ cell strainer, 100 µm (BD, Cat. No. 352360)
- Substrate of interest, highly purified, preferably by using endotoxin-free kits; A260:A280 ratio should be at least 1.8
- Cell culture vessels of your choice
- Culture medium: Use established culture media
- Prewarm appropriate volume of culture medium to 37°C
- Appropriate number of cells/sample (see Table 2)

## 1. Pre Nucleofection

### Cell culture recommendations

For general handling and culturing of cells please refer to the instructions of the cell supplier.

1. Cells should be in culture for at least 2 weeks prior to Nucleofection
2. Passage cells every 2 – 3 days after reaching  $1 - 2 \times 10^6$  cells/mL. Cells should not be used for Nucleofection™ after passage number 30
3. For passaging, resuspend cell suspension and dilute to  $2 - 4 \times 10^5$  cells/mL in fresh culture medium
4. Subculture 2 – 3 days before Nucleofection
5. Optimal density for Nucleofection:  $1 - 2 \times 10^6$  cells/mL. Higher cell densities may cause lower Nucleofection efficiencies

## 2. Nucleofection

For Nucleofection Sample contents and recommended Nucleofector™ Program, please refer to Table 2.

### Notes

- When working with large cell numbers consider the volume of the cell pellet before adding Nucleofector™ Solution. The total volume of cell pellet, Nucleofector™ Solution and substrate should match 1 mL (for 1 mL Nucleocuvette™ Cartridge) or up to 20 mL (for LV Nucleocuvette™ Cartridge).
- As leaving cells in Nucleofector™ Solution for extended periods of time may lead to reduced transfection efficiency and viability it is important to work as quickly as possible.
- Avoid air bubbles while pipetting.

### 2.1 Working with 1 mL Nucleocuvette™ Cartridges

1. Please ensure that the entire supplement is added to the Nucleofector™ Solution
2. Start 4D-Nucleofector™ System and select respective vessel type (1 mL LV Nucleocuvette™ Cartridge)
3. Create or upload experimental parameter file (for details see device manual)
4. Prepare cell culture vessels with desired volume of recommended culture media and pre-incubate vessels in a cell culture incubator
5. Prepare required amount of substrate (see Table 2)
6. Select the appropriate Nucleofector™ Program (see Table 2)
7. Count an aliquot of the cells and determine cell density
8. Centrifuge the required number of cells (see Table 2) at 90xg for 10 minutes at room temperature. Remove supernatant completely
9. Resuspend the cell pellet carefully in room temperature 4D-Nucleofector™ Solution (see Table 2)
10. Add required amount of substrate (e.g. plasmid DNA, mRNA) to the sample. Ensure that the volume of substrate solution added to each sample does not exceed 10% of the total reaction volume (i.e. 100 µL for a 1 mL reaction)
11. Transfer cell suspension supplemented with substrate into 1 mL Nucleocuvette™ Cartridge using a 1mL pipette
12. Insert Nucleocuvette™ Cartridge into the 4D-Nucleofector™ LV Unit. Ensure the Nucleocuvette™ Cartridge is correctly inserted
13. Start Nucleofection process by pressing “Start” on the display of the 4D-Nucleofector™ Core Unit (for details, please refer to the device manual)
14. After run completion, carefully remove the Nucleocuvette™ Cartridge from the slot
15. Remove sample from Nucleocuvette™ Cartridge using a 1 mL pipette
16. Pipet sample into culture vessel containing pre-warmed medium

## 2.2 Working with LV Nucleocuvette™ Cartridges

Before preparing the cells mount an LV Nucleocuvette™ Cartridge into the 4D-Nucleofector™ LV Unit (for details, please refer to the device manual).

1. Please ensure that the entire supplement is added to the Nucleofector™ Solution
2. Start 4D-Nucleofector™ System and select respective vessel type (LV Nucleocuvette™ Cartridge)
3. Create or upload experimental parameter file (for details see device manual) and select the appropriate Nucleofector™ Solution and Program (see Table 2)
4. Prepare cell culture vessels with desired volume of recommended culture media and pre-incubate vessels in a cell culture incubator
5. Prepare required amount of substrate (see Table 2)

Preparing the cells:

6. For adherent cells: Harvest the cells by trypsinization
7. Count an aliquot of the cells and determine cell density
8. Centrifuge the required number of cells (see Table 2) at 90xg for 10 minutes at room temperature. A higher centrifugation velocity may be required when using larger centrifugation vessels (e.g. 300xg for 500 mL). Ensure the cells are pelleted within 10 minutes.
9. Remove supernatant completely
10. Resuspend the cell pellet carefully in room temperature 4D-Nucleofector™ Solution (see Table 2)
11. Pipette cell suspension through a cell strainer into a Falcon tube

12. Loading the inlet reservoir(s):
  - a. **When working with one inlet reservoir:** Add required amount of substrate (e.g. plasmid DNA, mRNA) to the cell suspension; ensure that the volume of substrate solution added to each sample does not exceed 10% of the total reaction volume (i.e. 1 mL for a 10 mL reaction) to avoid significant dilution of the Nucleofector™ Solution by substrate buffer
  - b. **When working with two separate inlet reservoirs:** Keep substrate separately and optionally dilute it in Nucleofector™ Solution. The ratio of cell suspension to substrate should be kept between 1:1 to 10:1 to allow proper mixing. For ratios other than 1:10, please dilute substrate in Nucleofector™ Solution
13. Mount the inlet reservoir(s) or bag(s) into the reservoir holder(s)
14. Immediately start stirring the cell suspension at ~300 rpm to prevent cell sedimentation. Ensure that the magnet is truly stirring
15. Remove red caps from the Spiros connectors on the inlet tubes of the cartridge and the blue caps from the reservoir tubes and connect the tubes
16. Start Nucleofection process by pressing “Start” on the display of the 4D-Nucleofector™ Core Unit (for details, please refer to the device manual)
17. After run completion, carefully disconnect the outlet reservoir and transfer the cells in the culture system of your choice

## 3. Post Nucleofection

Until analysis, culture cells as usual in a cell culture incubator

**Table 1: Volumes Required for a 1 mL Reaction**

	1 mL Reaction
Volume of Nucleofector™ Solution	820 µL
Volume of Supplement	180 µL

**Table 2: Contents of One Nucleofection Sample and Recommended Program**

	Per 1 mL Reaction	Notes
Cells	1 – 5 x 10 <sup>7</sup>	Lower or higher cell numbers may influence transfection results
Substrate*	pmaxGFP™ Vector	Volume of substrate buffer added should not exceed 10% of total reaction volume to avoid significant dilution of the Nucleofector™ Solution by substrate buffer.
or	plasmid DNA (in H <sub>2</sub> O or TE)	
or	siRNA	
	Titrate optimal amount	
SF 4D-Nucleofector™ LV Solution	1 mL	
Program	FS-100	For other suspension HEK293 clones you may also try DJ-100

## 4. Additional Information

For an up-to-date list of all Nucleofector™ References, please refer to:  
[www.lonza.com/nucleofection-citations](http://www.lonza.com/nucleofection-citations)

**For more technical assistance, contact our Scientific Support Team:**

### USA /Canada

Phone: 800 521 0390 (toll-free)

Fax: 301 845 8338

E-mail: [scientific.support@lonza.com](mailto:scientific.support@lonza.com)

### Europe and Rest of World

Phone: +49 221 99199 400

Fax: +49 221 99199 499

E-mail: [scientific.support.eu@lonza.com](mailto:scientific.support.eu@lonza.com)

---

### Lonza Cologne GmbH

50829 Cologne, Germany

Please note that the Nucleofector™ Technology is not intended to be used for diagnostic purposes or for testing or treatment in humans.

The Nucleofector™ Technology, comprising Nucleofection process, Nucleofector™ Device, Nucleofector™ Solutions, Nucleofector™ 96-well Shuttle™ System and 96-well Nucleocuvette™ Plates and modules is covered by patent and/or patent-pending rights owned by Lonza Cologne GmbH.

Nucleofector, Nucleofection, 4D-Nucleofector, Nucleocuvette and maxGFP are registered trademarks of the Lonza Cologne GmbH in Germany and/or U.S. and/or other countries.

Other product and company names mentioned herein are the trademarks of their respective owners.

This kit contains a proprietary nucleic acid coding for a proprietary copepod fluorescent protein intended to be used as a positive control with this Lonza product only. Any use of the proprietary nucleic acid or protein other than as a positive control with this Lonza product is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at [license@evrogen.com](mailto:license@evrogen.com).

The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242.

All trademarks belong to Lonza or its affiliates or to their respective third party owners. The information contained herein is believed to be correct and corresponds to the latest state of scientific and technical knowledge. However, no warranty is made, either expressed or implied, regarding its accuracy or the results to be obtained from the use of such information and no warranty is expressed or implied concerning the use of these products. The buyer assumes all risks of use and/or handling. Any user must make his own determination and satisfy himself that the products supplied by Lonza Group Ltd or its affiliates and the information and recommendations given by Lonza Group Ltd or its affiliates are (i) suitable for intended process or purpose, (ii) in compliance with environmental, health and safety regulations, and (iii) will not infringe any third party's intellectual property rights.

©2017, Lonza. All rights reserved.

D4LC-2001\_2017-08

---